Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-adapted therapy for stage III-IV Hodgkin lymphoma (S0816)
NCT00822120Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2009
- Primary completion
- Apr 2016
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin, bleomycin, vinblastine, dacarbazine, cyclophosphamide in Hodgkin lymphoma (HL), sponsored by SWOG Cancer Research Network. Started Jul 2009; status: completed.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazinecyclophosphamide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00822120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00822120.